about
Elucidating immune mechanisms causing hypertension during pregnancyAbsence of neurotoxicity with medicinal grade terbutaline in the rat model.Progesterone blunts vascular endothelial cell secretion of endothelin-1 in response to placental ischemiaThe role of inflammation in the pathology of preeclampsiaHypertension, inflammation and T lymphocytes are increased in a rat model of HELLP syndromeEnodthelin 1 is elevated in plasma and explants from patients having uterine leiomyomas.Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia.Prenatal infection decreases calbindin, decreases Purkinje cell volume and density and produces long-term motor deficits in Sprague-Dawley rats.CD4+ T cells are important mediators of oxidative stress that cause hypertension in response to placental ischemia.Plasma from patients with HELLP syndrome increases blood-brain barrier permeability.Preventing autoimmunity protects against the development of hypertension and renal injury.Hypertension in response to CD4(+) T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system.An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia.Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia.The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy.Identifying immune mechanisms mediating the hypertension during preeclampsiaEndothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancyAdministration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy.Dysregulation of the Fas/FasL system in an experimental animal model of HELLP syndrome.Pathophysiology and Current Clinical Management of Preeclampsia.Inhibition of T-cell activation attenuates hypertension, TNFα, IL-17, and blood-brain barrier permeability in pregnant rats with angiogenic imbalance.Hypertension in an Animal Model of HELLP Syndrome is Associated With Activation of Endothelin 1.Low-dose testosterone protects against renal ischemia-reperfusion injury by increasing renal IL-10-to-TNF-α ratio and attenuating T-cell infiltration.Clomiphene citrate versus letrozole: molecular analysis of the endometrium in women with polycystic ovary syndrome.Postpartum thrombotic microangiopathic syndrome.Reduced uterine perfusion pressure T-helper 17 cells cause pathophysiology associated with preeclampsia during pregnancy.Posterior reversible encephalopathy syndrome in 46 of 47 patients with eclampsia.Selective inhibition of 20-hydroxyeicosatetraenoic acid lowers blood pressure in a rat model of preeclampsia.Vitamin D supplementation reduces some AT1-AA-induced downstream targets implicated in preeclampsia including hypertension.The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and designNovel treatment avenues for uterine leiomyoma: A new implication for Endothelin?Peripheral Anti-Angiogenic Imbalance during Pregnancy Impairs Myogenic Tone and Increases Cerebral Edema in a Rodent Model of HELLP SyndromeDecidual natural killer cells: A critical pregnancy mediator altered in preeclampsiaAn immunohistochemical assay to detect trophoblasts in frozen feline placentaHypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertensionDepo-medroxyprogesterone acetate, weight gain and amenorrhea among obese adolescent and adult women
P50
Q26852668-DACE59DF-CCC8-4F65-B573-F9B3342EDA67Q30574999-E872F379-EB0A-4906-979A-731263D66ED1Q33736407-30DE7684-B189-4EA2-A9F8-80542CE64EA1Q33834419-6D6FE605-7251-4538-AB1B-9E6997B2175AQ34025660-01E336A3-74BE-4DC3-8176-E9B6E5DD73DFQ34418125-093572AC-2920-4BE9-AB80-A4E8C9C40CF4Q34785813-C705F9E7-0E78-4054-875D-37D06C4EE162Q35069806-02068BDA-5C21-4BA8-A52E-658A412B4C65Q35153877-0EBB24E8-FE61-4F16-B0BB-1C99848FC187Q35155096-CEDF32D4-FDDE-4C08-B560-92C8EEFB536DQ35159241-742AC3F5-EB3C-43E3-9281-B348B2C258DDQ36115279-240D292A-5896-4BC1-9B33-0D2C9E9586B3Q36339336-64A848C4-35B3-41C6-AB69-3B78593A0363Q36355165-E80DB0D9-9AB5-421C-95CF-03B323AF8388Q36407259-6A685DDA-6553-4B78-8AE1-651FCCF95486Q37139722-C92CFD35-AF32-4509-BB6A-77C5576FC1A8Q37353537-6DDD8909-B5CA-437C-B474-6FE3FF57F1AAQ37507162-72370B6D-0C18-4F31-B26C-44C7F1E2B5BCQ38684330-83C8DC37-E43B-4DAC-87AB-CC248282153EQ39423454-18A5B9A5-D580-4202-B99E-559967A48A17Q39540875-C648026F-C705-4AFA-B94A-AA67CF88AB6FQ40779892-0A0603C4-A11B-4294-9432-51A8221A6AD8Q40998899-3FF4CCB4-B0F2-4628-A6FF-8316DC2EFC27Q42727476-3AB4B243-6217-4691-9D62-FB0DAAF38D7CQ43963039-CC046B41-82D3-45CA-8DF2-CE3AF7F2A4EAQ45848306-68B60CD7-7388-4080-A134-E923088031D9Q48169612-699DE8F7-4BF2-4C9A-ADC1-75F12A6E71A3Q49813818-176403B4-9763-4F0D-B5BF-8D07D5B18467Q51294484-85D73293-68C4-43D5-B2B8-4E6834DAA949Q57177561-A71AFA0C-5225-4DE2-B28B-1D78CD29AD85Q57288234-4C4449DA-543A-436F-9C30-134A9A876539Q60912330-731FC1DE-9709-4ACA-83A0-75A845B36C21Q61812466-78D4000F-ABC1-42B8-A716-E6FB80FC8029Q83600222-EA25D46C-18A0-478E-8912-5481C77296DDQ83799951-71C96FAE-233B-4CDF-BB7B-4E1EA473BD79Q92582924-164F83AF-37E5-475C-9A9D-B34C011EEA81
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kedra Wallace
@ast
Kedra Wallace
@en
Kedra Wallace
@es
Kedra Wallace
@nl
Kedra Wallace
@sl
type
label
Kedra Wallace
@ast
Kedra Wallace
@en
Kedra Wallace
@es
Kedra Wallace
@nl
Kedra Wallace
@sl
prefLabel
Kedra Wallace
@ast
Kedra Wallace
@en
Kedra Wallace
@es
Kedra Wallace
@nl
Kedra Wallace
@sl
P106
P1153
7102664942
P31
P496
0000-0003-4511-0046